Aclarion Secures U.S. Patent for MRS Data Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy ACON?
Aclarion announced the issuance of a U.S. patent covering its machine learning-based platform for analyzing magnetic resonance spectroscopy, or MRS, data. Aclarion's cloud-based platform, Nociscan, converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. The patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. The patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACON
Wall Street analysts forecast ACON stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.390
Low
23.00
Averages
23.00
High
23.00
Current: 3.390
Low
23.00
Averages
23.00
High
23.00
No data
About ACON
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ACLARION REVEALS PARTNERSHIP WITH WEILL CORNELL MEDICINE
Announcement of Agreement: Aclarion has announced a new agreement with Weill Cornell Medicine.
Collaboration Focus: The partnership aims to enhance medical research and innovation in healthcare.
See More
Aclarion Releases 2026 Shareholder Letter Highlighting Key Milestones
- Strengthened Financial Position: Aclarion's recent financings provide a cash runway into 2028, ensuring that the company can complete its 300-patient CLARITY trial and achieve initial data readout without raising additional capital, thereby boosting shareholder confidence.
- Clinical Trial Progress: The company anticipates an initial internal readout of the CLARITY trial by the end of Q3 2026, with public disclosure of early interim results expected in Q4, which will provide critical data support for its technology in the chronic low back pain market.
- Optimized Capital Structure: Aclarion has terminated its ATM and allowed its ELOC to expire at the end of 2025, indicating that the company will not pursue new capital raises in the near term, further solidifying its clean capital structure.
- Software-Driven Innovation: As a new generation of software-native MedTech innovator, Aclarion's Nociscan platform delivers solutions entirely through the cloud, enabling rapid scalability and continuous algorithmic improvements, which are expected to significantly enhance its competitive position in the market.
See More
Aclarion CEO Outlines 2026 Execution Plan Focused on Reimbursement and Adoption
- Market Opportunity Analysis: CEO Brent Ness highlighted that approximately 266 million people globally suffer from chronic low back pain, with Aclarion's market opportunity spanning spinal fusion surgeries, non-fusion procedures, and pain management, which are expected to increase scan volumes over time, driving revenue growth.
- Early Revenue Sources: Aclarion is generating revenue from Nociscan scans in the UK, cash-pay usage, and clinical trials, particularly in London where insurance coverage reduces financial friction for physicians and patients, thereby supporting higher scan utilization and growth.
- Clinical Trials and Reimbursement Pathway: Aclarion's Clarity trial aims to enroll 300 patients and features an early-stop design to accelerate discussions with insurers, with findings indicating that Nociscan reduces costs by about $1,700 per patient, strengthening the case for payer adoption.
- Comparison with HeartFlow: Ness compared Aclarion's strategy to HeartFlow, which saw quarterly revenue grow from $26.8 million to $46.3 million in 2025, illustrating the challenges Aclarion faces in regaining investor confidence and improving market performance.
See More
Aclarion Expands Nociscan Availability in Greater Los Angeles
- Market Expansion Strategy: Aclarion has established an agreement with Source Healthcare in Los Angeles to introduce Nociscan, aiming to fill a critical gap in chronic low back pain treatment, thereby enhancing the company's market share in this sector.
- Clinical Validation Advantage: Nociscan, as a non-invasive alternative, objectively measures pain and structural integrity biomarkers in spinal discs through an MRI-like experience, providing clinical validation compared to anesthetic discography, further solidifying its application potential in pain management.
- Data Asset Development: By collaborating with a high-volume clinical practice, Aclarion will strengthen the evidence base for Nociscan, supporting its adoption in the broader pain management market, which is expected to drive payer and provider acceptance.
- Improved Success Rates: Research indicates that Nociscan has improved outcomes and reduced costs in the spinal fusion market, with a 97% surgical success rate, highlighting its potential value among chronic low back pain patients and further advancing the company's strategic position in the healthcare technology field.
See More
Aclarion, Inc. Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion closed a $10.4 million common stock financing priced at $5.18 per share, which enhances the company's balance sheet and strategic flexibility, supporting Nociscan's clinical and commercial growth.
- Extended Cash Runway: As of January 12, 2026, the company reported $21.6 million in cash with zero debt, extending its cash runway into 2028 based on current operating plans, ensuring operational capacity ahead of key milestones.
- Accelerated Clinical Validation: Aclarion aims to speed up patient enrollment in the CLARITY trial to approximately 25% by the end of Q2 2026, while also conducting several real-world evidence studies to expand market opportunities by over 30%.
- Technology Upgrade and Market Expansion: The company plans to launch Nociscan version 2.8 in Q1 to improve workflow integration and is actively engaging with multiple U.S. commercial payers to advance broader reimbursement for Nociscan, enhancing its competitive position in the market.
See More
Aclarion Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion has closed a $10.4 million common stock financing at $5.18 per share, significantly strengthening the company's balance sheet and ensuring the integrity of its capital structure for future growth.
- Increased Cash Reserves: As of January 12, 2026, Aclarion holds $21.6 million in cash with zero debt, extending its cash runway into 2028, which secures operational stability for the coming years.
- Accelerated Clinical Validation: The company aims to enroll approximately 25% of patients in the CLARITY trial by the end of Q2 2026, with initial results available internally after the three-month follow-up, expediting the clinical validation of Nociscan.
- Market Expansion Strategy: Aclarion plans to grow access to major MRI manufacturers, increasing the global market size by over 30%, while enhancing clinician education and awareness through participation in CME events to further penetrate the market with Nociscan.
See More
ACLARION REVEALS PARTNERSHIP WITH WEILL CORNELL MEDICINE
Announcement of Agreement: Aclarion has announced a new agreement with Weill Cornell Medicine.
Collaboration Focus: The partnership aims to enhance medical research and innovation in healthcare.
See More
Aclarion Releases 2026 Shareholder Letter Highlighting Key Milestones
- Strengthened Financial Position: Aclarion's recent financings provide a cash runway into 2028, ensuring that the company can complete its 300-patient CLARITY trial and achieve initial data readout without raising additional capital, thereby boosting shareholder confidence.
- Clinical Trial Progress: The company anticipates an initial internal readout of the CLARITY trial by the end of Q3 2026, with public disclosure of early interim results expected in Q4, which will provide critical data support for its technology in the chronic low back pain market.
- Optimized Capital Structure: Aclarion has terminated its ATM and allowed its ELOC to expire at the end of 2025, indicating that the company will not pursue new capital raises in the near term, further solidifying its clean capital structure.
- Software-Driven Innovation: As a new generation of software-native MedTech innovator, Aclarion's Nociscan platform delivers solutions entirely through the cloud, enabling rapid scalability and continuous algorithmic improvements, which are expected to significantly enhance its competitive position in the market.
See More
Aclarion CEO Outlines 2026 Execution Plan Focused on Reimbursement and Adoption
- Market Opportunity Analysis: CEO Brent Ness highlighted that approximately 266 million people globally suffer from chronic low back pain, with Aclarion's market opportunity spanning spinal fusion surgeries, non-fusion procedures, and pain management, which are expected to increase scan volumes over time, driving revenue growth.
- Early Revenue Sources: Aclarion is generating revenue from Nociscan scans in the UK, cash-pay usage, and clinical trials, particularly in London where insurance coverage reduces financial friction for physicians and patients, thereby supporting higher scan utilization and growth.
- Clinical Trials and Reimbursement Pathway: Aclarion's Clarity trial aims to enroll 300 patients and features an early-stop design to accelerate discussions with insurers, with findings indicating that Nociscan reduces costs by about $1,700 per patient, strengthening the case for payer adoption.
- Comparison with HeartFlow: Ness compared Aclarion's strategy to HeartFlow, which saw quarterly revenue grow from $26.8 million to $46.3 million in 2025, illustrating the challenges Aclarion faces in regaining investor confidence and improving market performance.
See More
Aclarion Expands Nociscan Availability in Greater Los Angeles
- Market Expansion Strategy: Aclarion has established an agreement with Source Healthcare in Los Angeles to introduce Nociscan, aiming to fill a critical gap in chronic low back pain treatment, thereby enhancing the company's market share in this sector.
- Clinical Validation Advantage: Nociscan, as a non-invasive alternative, objectively measures pain and structural integrity biomarkers in spinal discs through an MRI-like experience, providing clinical validation compared to anesthetic discography, further solidifying its application potential in pain management.
- Data Asset Development: By collaborating with a high-volume clinical practice, Aclarion will strengthen the evidence base for Nociscan, supporting its adoption in the broader pain management market, which is expected to drive payer and provider acceptance.
- Improved Success Rates: Research indicates that Nociscan has improved outcomes and reduced costs in the spinal fusion market, with a 97% surgical success rate, highlighting its potential value among chronic low back pain patients and further advancing the company's strategic position in the healthcare technology field.
See More
Aclarion, Inc. Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion closed a $10.4 million common stock financing priced at $5.18 per share, which enhances the company's balance sheet and strategic flexibility, supporting Nociscan's clinical and commercial growth.
- Extended Cash Runway: As of January 12, 2026, the company reported $21.6 million in cash with zero debt, extending its cash runway into 2028 based on current operating plans, ensuring operational capacity ahead of key milestones.
- Accelerated Clinical Validation: Aclarion aims to speed up patient enrollment in the CLARITY trial to approximately 25% by the end of Q2 2026, while also conducting several real-world evidence studies to expand market opportunities by over 30%.
- Technology Upgrade and Market Expansion: The company plans to launch Nociscan version 2.8 in Q1 to improve workflow integration and is actively engaging with multiple U.S. commercial payers to advance broader reimbursement for Nociscan, enhancing its competitive position in the market.
See More
Aclarion Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion has closed a $10.4 million common stock financing at $5.18 per share, significantly strengthening the company's balance sheet and ensuring the integrity of its capital structure for future growth.
- Increased Cash Reserves: As of January 12, 2026, Aclarion holds $21.6 million in cash with zero debt, extending its cash runway into 2028, which secures operational stability for the coming years.
- Accelerated Clinical Validation: The company aims to enroll approximately 25% of patients in the CLARITY trial by the end of Q2 2026, with initial results available internally after the three-month follow-up, expediting the clinical validation of Nociscan.
- Market Expansion Strategy: Aclarion plans to grow access to major MRI manufacturers, increasing the global market size by over 30%, while enhancing clinician education and awareness through participation in CME events to further penetrate the market with Nociscan.
See More
